177 related articles for article (PubMed ID: 32677906)
21. Arginine deiminase PEG20 inhibits growth of small cell lung cancers lacking expression of argininosuccinate synthetase.
Kelly MP; Jungbluth AA; Wu BW; Bomalaski J; Old LJ; Ritter G
Br J Cancer; 2012 Jan; 106(2):324-32. PubMed ID: 22134507
[TBL] [Abstract][Full Text] [Related]
22. TRAIL induces autophagic protein cleavage through caspase activation in melanoma cell lines under arginine deprivation.
You M; Savaraj N; Kuo MT; Wangpaichitr M; Varona-Santos J; Wu C; Nguyen DM; Feun L
Mol Cell Biochem; 2013 Feb; 374(1-2):181-90. PubMed ID: 23180246
[TBL] [Abstract][Full Text] [Related]
23. Arginine deiminase resistance in melanoma cells is associated with metabolic reprogramming, glucose dependence, and glutamine addiction.
Long Y; Tsai WB; Wangpaichitr M; Tsukamoto T; Savaraj N; Feun LG; Kuo MT
Mol Cancer Ther; 2013 Nov; 12(11):2581-90. PubMed ID: 23979920
[TBL] [Abstract][Full Text] [Related]
24. Arginine Deiminase Induces Immunogenic Cell Death and Is Enhanced by
Huang Z; Hu H
Molecules; 2021 Jan; 26(2):. PubMed ID: 33478072
[TBL] [Abstract][Full Text] [Related]
25. Selective Intracellular Delivery of Recombinant Arginine Deiminase (ADI) Using pH-Sensitive Cell Penetrating Peptides To Overcome ADI Resistance in Hypoxic Breast Cancer Cells.
Yeh TH; Chen YR; Chen SY; Shen WC; Ann DK; Zaro JL; Shen LJ
Mol Pharm; 2016 Jan; 13(1):262-71. PubMed ID: 26642391
[TBL] [Abstract][Full Text] [Related]
26. Activation of Ras/PI3K/ERK pathway induces c-Myc stabilization to upregulate argininosuccinate synthetase, leading to arginine deiminase resistance in melanoma cells.
Tsai WB; Aiba I; Long Y; Lin HK; Feun L; Savaraj N; Kuo MT
Cancer Res; 2012 May; 72(10):2622-33. PubMed ID: 22461507
[TBL] [Abstract][Full Text] [Related]
27. Combination of arginine deprivation with TRAIL treatment as a targeted-therapy for mesothelioma.
Wangpaichitr M; Wu C; Bigford G; Theodoropoulos G; You M; Li YY; Verona-Santos J; Feun LG; Nguyen DM; Savaraj N
Anticancer Res; 2014 Dec; 34(12):6991-9. PubMed ID: 25503125
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of arginine depletion by ADI-PEG20 in an intracranial model of GBM.
Przystal JM; Hajji N; Khozoie C; Renziehausen A; Zeng Q; Abaitua F; Hajitou A; Suwan K; Want E; Bomalaski J; Szlosarek P; O'Neill K; Crook T; Syed N
Cell Death Dis; 2018 Dec; 9(12):1192. PubMed ID: 30546006
[TBL] [Abstract][Full Text] [Related]
29. Drug evaluation: ADI-PEG-20--a PEGylated arginine deiminase for arginine-auxotrophic cancers.
Shen LJ; Shen WC
Curr Opin Mol Ther; 2006 Jun; 8(3):240-8. PubMed ID: 16774044
[TBL] [Abstract][Full Text] [Related]
30. Genome-wide CRISPR/Cas9 knockout screening uncovers a novel inflammatory pathway critical for resistance to arginine-deprivation therapy.
Chu CY; Lee YC; Hsieh CH; Yeh CT; Chao TY; Chen PH; Lin IH; Hsieh TH; Shih JW; Cheng CH; Chang CC; Lin PS; Huang YL; Chen TM; Yen Y; Ann DK; Kung HJ
Theranostics; 2021; 11(8):3624-3641. PubMed ID: 33664852
[TBL] [Abstract][Full Text] [Related]
31. Down-regulation of argininosuccinate synthetase is associated with cisplatin resistance in hepatocellular carcinoma cell lines: implications for PEGylated arginine deiminase combination therapy.
McAlpine JA; Lu HT; Wu KC; Knowles SK; Thomson JA
BMC Cancer; 2014 Aug; 14():621. PubMed ID: 25164070
[TBL] [Abstract][Full Text] [Related]
32. A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma.
Phillips MM; Pavlyk I; Allen M; Ghazaly E; Cutts R; Carpentier J; Berry JS; Nattress C; Feng S; Hallden G; Chelala C; Bomalaski J; Steele J; Sheaff M; Balkwill F; Szlosarek PW
Pharmacol Rep; 2023 Jun; 75(3):570-584. PubMed ID: 37010783
[TBL] [Abstract][Full Text] [Related]
33. Assessment of pegylated arginine deiminase and modified FOLFOX6 in patients with advanced hepatocellular carcinoma: Results of an international, single-arm, phase 2 study.
Harding JJ; Yang TS; Chen YY; Feng YH; Yen CJ; Ho CL; Huang WT; El Dika I; Akce M; Tan B; Cohen SA; Meyer T; Sarker D; Lee DW; Ryoo BY; Lim HY; Johnston A; Bomalaski JS; O'Reilly EM; Qin S; Abou-Alfa GK
Cancer; 2021 Dec; 127(24):4585-4593. PubMed ID: 34415578
[TBL] [Abstract][Full Text] [Related]
34. Discovery and Targeting of a Noncanonical Mechanism of Sarcoma Resistance to ADI-PEG20 Mediated by the Microenvironment.
Rogers LC; Kremer JC; Brashears CB; Lin Z; Hu Z; Bastos ACS; Baker A; Fettig N; Zhou D; Shoghi KI; Dehner CA; Chrisinger JSA; Bomalaski JS; Garcia BA; Oyama T; White EP; Van Tine BA
Clin Cancer Res; 2023 Aug; 29(16):3189-3202. PubMed ID: 37339179
[TBL] [Abstract][Full Text] [Related]
35. A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients.
Tsai HJ; Jiang SS; Hung WC; Borthakur G; Lin SF; Pemmaraju N; Jabbour E; Bomalaski JS; Chen YP; Hsiao HH; Wang MC; Kuo CY; Chang H; Yeh SP; Cortes J; Chen LT; Chen TY
Sci Rep; 2017 Sep; 7(1):11253. PubMed ID: 28900115
[TBL] [Abstract][Full Text] [Related]
36. Pegylated arginine deiminase depletes plasma arginine but maintains tissue arginine availability in young pigs.
Mohammad MA; Didelija IC; Stoll B; Nguyen TC; Marini JC
Am J Physiol Endocrinol Metab; 2021 Mar; 320(3):E641-E652. PubMed ID: 33427052
[TBL] [Abstract][Full Text] [Related]
37. Arginine-lowering enzymes against cancer: a technocommercial analysis through patent landscape.
Dhankhar R; Gulati P; Kumar S; Kapoor RK
Expert Opin Ther Pat; 2018 Aug; 28(8):603-614. PubMed ID: 30092168
[TBL] [Abstract][Full Text] [Related]
38. Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase.
Feun LG; Marini A; Walker G; Elgart G; Moffat F; Rodgers SE; Wu CJ; You M; Wangpaichitr M; Kuo MT; Sisson W; Jungbluth AA; Bomalaski J; Savaraj N
Br J Cancer; 2012 Apr; 106(9):1481-5. PubMed ID: 22472884
[TBL] [Abstract][Full Text] [Related]
39. Mono-PEGylation of a Thermostable Arginine-Depleting Enzyme for the Treatment of Lung Cancer.
Chung SF; Kim CF; Kwok SY; Tam SY; Chen YW; Chong HC; Leung SL; So PK; Wong KY; Leung YC; Lo WH
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32545874
[TBL] [Abstract][Full Text] [Related]
40. Arginine deprivation by arginine deiminase of Streptococcus pyogenes controls primary glioblastoma growth in vitro and in vivo.
Fiedler T; Strauss M; Hering S; Redanz U; William D; Rosche Y; Classen CF; Kreikemeyer B; Linnebacher M; Maletzki C
Cancer Biol Ther; 2015; 16(7):1047-55. PubMed ID: 25774632
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
